Detalles de la búsqueda
1.
Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysis.
Helicobacter
; 27(5): e12914, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35848363
2.
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan.
J Gastroenterol Hepatol
; 35(2): 233-240, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31408909
3.
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
J Antimicrob Chemother
; 73(9): 2510-2518, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846605
4.
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Lancet Gastroenterol Hepatol
; 8(3): 228-241, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36549320
5.
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Lancet Gastroenterol Hepatol
; 8(7): 623-634, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37178702
6.
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial.
Therap Adv Gastroenterol
; 13: 1756284820927306, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32821287
Resultados
1 -
6
de 6
1
Próxima >
>>